Richard A. Vogel

Modification of the actions of ethanol by centrally active peptides

Ethanol (2.0-5.0 g/kg, IP) caused a dose-related impairment of the aerial righting reflex of mice 60 min after injection. Ethanol (3.5 g/kg, IP) given simultaneously with neurotensin (30 micrograms, IC), bombesin (30 micrograms, IC) or beta-endorphin (20 micrograms, IC) caused a greater impairment of the reflex than ethanol alone. Simultaneous treatment with ethanol (4.0 g/kg, IP) and thyrotropin-releasing hormone (TRH, 3.0-30 micrograms, IC) caused less impairment of this measure than ethanol alone. None of the peptides altered the height of aerial righting when administered alone, or when administered with ethanol no peptide altered blood or brain ethanol content. Unexpectedly, TRH (20 and 40 mg/kg, IP) potentiated the action of ethanol by increasing punished licking in water-deprived rats, rather than antagonizing this acute action of ethanol. Like ethanol (1.0 and 2.0 g/kg, IP), beta-endorphin (100 micrograms, IC) suppressed ethanol-withdrawal tremor and audiogenic-seizure susceptibility in ethanol-dependent rats. beta-Endorphin (1 microgram) and bombesin (10 and 30 micrograms, IC) reduced only audiogenic-seizure susceptibility. TRH (10-100 micrograms, IC, or 1-40 mg/kg, IV) and neurotensin (10-100 micrograms, IC) had no effect on these ethanol-withdrawal signs. These findings suggest that centrally active peptides may play a role in certain acute and chronic actions of ethanol. Because TRH, neurotensin, bombesin and beta-endorphin do not alter all actions of ethanol in the same way, an interaction of ethanol with many functionally independent neuronal circuits is suggested.

Attenuation of the effects of punishment by ethanol: Comparisons with chlordiazepoxide

Ethanol (ETOH), like chlordiazepoxide (CDZ), significantly attenuated the suppressive effect of punishment on licking behavior in water-deprived rats and mice. In rats, the greatest effects of ETOH (1.5 g/kg) were observed between 30 and 60 min following IP administration. tert-Butanol also attenuated the effects of punishment, suggesting that acetaldehyde was not contributing to this effect of ETOH. Since a dose of ETOH that increased punished drinking did not increase unpunished drinking, alteration in thirst motivation would not appear to be responsible for its antipunishment action. However, doses of ETOH or CDZ that significantly increased punished responding increased jump thresholds to aversive shock, suggesting that decreased sensitivity to aversive stimulation may contribute to the anti-punishment action of both agents. In addition to these similarities between ethanol and CDZ, several differences were noted in their effects. For example, CDZ decreased serum corticosterone concentration, whereas ETOH did not. Further, ETOH impaired aerial righting reflex and reduced rectal temperature, whereas CDZ had no effect on these parameters at doses that had anti-punishment activity. Finally, specific binding of [3H]flunitrazepam to crude brain cortical membranes was decreased by CDZ, but not ETOH. Although ETOH and CDZ similarly alter punished behavior, results suggest that ETOH does not act through a direct interaction with a benzodiazepine binding site.

Effect of 5,7-dihydroxytryptamine on serotonergic control of prolactin secretion and behavior in rats

The intracisternal administration of 5,7-dihydroxytryptamine (5,7-DHT) to rats resulted in a potentiated response to 5-hydroxytryptophan (5-HTP) when the animals were tested 30 days later. The 5-HTP-induced changes include elevation of serum prolactin decrease in operant responding, and the magnitude of the “serotonin behavioral syndrome” observed after 5-HTP administration. The serotonin concentration in brains of 5,7-DHT-treated animals reached maximum earlier and remained elevated longer than that of controls following administration of 5-HTP. Brain norepinephrine and dopamine concentration were not affected by 5-HTP in either group of animals. The increase in serum prolactin concentration elicited by administration of the serotonergic agonists quipazine or 5-methyxy-N,N-dimethyltryptamine and by the serotonin uptake inhibitor fenfluramine also was potentiated by pretreating rats with 5,7-DHT. These data suggest that both serotonergic receptor supersensitivity and the absence of presynaptic uptake sites contribute to the enhanced responses to 5-HTP occurring in rats previously treated with 5,7-DHT. The findings further demonstrate that both behavioral and hormonal measures can be used to assess the sensitivity of serotonergic receptors and indicate that 5,7-DHT may be useful in evaluating the role of serotonergic neurons in neuroendocrine function.

Behavioral and prolactin responses to 5-hydroxytrytophan in rats treated during development with 5,7-dihydroxytryptamine

The serotonin precursor, 5-hydroxytryptophan (5-HTP), can induce a behavioral syndrome characterized by rigidity, splayed feet, tremor, head weaving, salivation and forepaw treading. This response to 5-HTP was markedly potentiated in adult rats treated intracisternally with 5,7-dihydroxytryptamine (5,7-DHT) during development. Prevention of the 5,7-DHT-induced reduction of brain norepinephrine with pargyline or desipramine did not diminish the potentiation of 5-HTP, suggesting that noradrenergic fibers are not contributing to the altered 5-HTP response. It was also found that treatments with 5,7-DHT potentiated the release of prolactin and the disruption of responding in a fixed-ratio operant task induced by 5-HTP. Other experiments indicated that 5,7-DHT treatments potentiated 5-HTP without affecting the action of L-dihydroxyphenylalanine. In addition, administration of the decarboxylase inhibitor, R0-4-4602, at a dose that inhibits enzyme activity in brain, blocked the 5-HTP-induced behavioral syndrome in 5,7-DHT-treated rats, indicating that 5-HTP must be converted to serotonin for 5-HTP to alter behavior. Thus, the present studies indicate that destruction of serotonergic fibers during development can produce permanent changes in central serotonergic mechanisms.

An evaluation of the selectivity of fenmetozole (DH-524) reversal of ethanol-induced changes in central nervous system function

The selectivity and specificity of fenmetozole (DH-524) [2(3,4-dichlorophenoxy-methy))2-imidazole HCl] as an antagonist of the actions of ethanol were examined. Fenmetozole (15–30 g/kg) reduced ethanol-induced impairment of the aerial righting reflex without changing blood or brain ethanol content, indicating that the antagonistic actions of fenmetozole were not due to change in the pharmacokinetics of ethanol. Since fenmetozole also reduced aerial righting reflex impairment due to phenobarbital, chlordiazepoxide, and halothane, this action of fenmetozole was not specific to ethanol. In mice, both the ethanolinduced increase in locomotor activity at 2.0 g/kg and the decrease caused by 4.0 g/kg were antagonized by fenmetozole. In addition, fenmetozole attenuated the ethanol-induced reduction in cerebellar cyclic guanosine monophosphate (cGMP) content, but the drug also significantly elevated cGMP levels in this tissue when given alone. Fenmetozole did not alter ethanolinduced increases in punished drinking in a conflict test, except at a high dose which alone decreased both punished and unpunished responding. Fenmetozole also failed to precipitate ethanol withdrawal-like reactions when given to physically-dependent, intoxicated rats. Thus, the antagonistic action of fenmetozole against ethanol would not seem to be related to a specific receptor interaction but rather may be the result of a physiological antagonism.

An efficient chronic conflict paradigm: Lick suppression by incremental footshock

A conflict paradigm was designed which uses water as the reinforcer and incremental footshock as the punishment. It is easy to initiate responding and to maintain stable baselines over long periods of time. This paradigm proved selective for clinically effective anxiolytic compounds while a number of psychotropic compounds, which have no clinical anxiolytic activity, were not effective.

A comparison of behavioral and neurochemical effects of ethanol and chlordiazepoxide.

Many similarities were observed in the behavioral and neurochemical actions of ethanol and chlordiazepoxide (CDZ) suggesting that these agents may share common mechanisms of action. However, similarities in these actions could not be explained by effects on a benzodiazepine binding site, since only CDZ interacted with this locus.

An alternative to animal models of central nervous system disorders: Study of drug mechanisms and disease symptoms in animals

Abstract 1. 1. Attempts to produce complete animal models of human disorders of the CNS have had limited success. 2. 2. By having alternative approaches to the production of “true” models of CNS disease, animal research has been able to make significant contributions to our understanding of central disease mechanisms. 3. 3. One alternative includes an examination of the mechanism(s) of action of drugs which alter symptoms of disorders of the CNS. 4. 4. Another approach has been the study of underlying neurobiological mechanisms of individual functions which are abnormal in central diseases. 5. 5. This overview provides examples of research which have extended our knowledge about CNS disorders and outlines some of the difficulties in interpretation encountered when these approaches are used.

Drug alterations of punished responding after chlordiazepoxide: Possible screen for agents useful in minimal brain dysfunction

In the present study, the effect of various stimulant drugs on the action of chlordiazepoxide to increase punished responding was studied. Drugs such as d-amphetamine, methylphenidate and imipramine that are effective in attentional deficit disorder (MBD) were found to reverse this benzodiazepine-induced increase in responding. Phenobarbital which worsens this condition enhanced the benzodiazepine effect. Since the impairment caused by chlordiazepoxide may be analogous to the lack of impulse control noted in MBD, the bupropion antagonism of this action of chlordiazepoxide suggests that bupropion may be useful in MBD.